Muscular Dystrophy, Duchenne Clinical Trial
Official title:
Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care
This study is being performed as a post-approval safety study (PASS), per the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), to gather data on Translarna (ataluren) safety, effectiveness, and prescription patterns in routine clinical practice.
This is a multicenter, observational study of participants receiving Translarna based on inclusion of their data in a registry. This study is intended to enroll 360 participants across ~50 care centers in Europe and other regions over a period of ~ 2 years. The study population will include participants who are receiving usual care treatment with commercial supply of Translarna (or receiving care within a named participant early access program) and who provide consent. Participants will be followed for at least 5 years from their date of enrollment. Safety and efficacy data will be collected in conjunction with routine visits conducted as per usual care. Although there are no protocol-mandated procedures, it is expected that physicians and other caregivers will follow published treatment guidelines and standards of care. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01865084 -
A Study of Tadalafil for Duchenne Muscular Dystrophy
|
Phase 3 | |
| Completed |
NCT00243789 -
Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
| Completed |
NCT00033189 -
An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy
|
Phase 2 | |
| Completed |
NCT03703882 -
Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
|
Phase 3 | |
| Enrolling by invitation |
NCT04626674 -
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
|
Phase 1 | |
| Completed |
NCT02286947 -
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
|
Phase 2 | |
| Completed |
NCT03406780 -
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 2 | |
| Completed |
NCT01826487 -
Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
|
Phase 3 | |
| Completed |
NCT02710591 -
Rimeporide in Patients With Duchenne Muscular Dystrophy
|
Phase 1 | |
| Completed |
NCT01826422 -
Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients
|
N/A | |
| Completed |
NCT00102453 -
Pentoxifylline in Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
| Terminated |
NCT02090959 -
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
|
Phase 3 | |
| Recruiting |
NCT05833633 -
Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations
|
||
| Completed |
NCT05209087 -
Effects of Parental Influence on Physical Activity Level and Participation in Children With Duchenne Muscular Dystrophy
|
||
| Completed |
NCT03789734 -
Safety Study of BLS-M22 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT05126758 -
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 3 | |
| Completed |
NCT00016653 -
Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy
|
Phase 2/Phase 3 | |
| Completed |
NCT03127241 -
User-centred Assistive System for Arm Functions in Neuromuscular Subjects
|
N/A | |
| Completed |
NCT03490214 -
Non-invasive Imaging of Muscle Structure in Duchenne Muscular Dystrophy Using Multispectral Optoacoustic Tomography
|
N/A | |
| Completed |
NCT03179631 -
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
|
Phase 3 |